A study published in the European Heart Journal (2012; 33(13):1582–1588; doi:10.1093/eurheartj/ehr499) examined cardiovascular outcomes in 3,740 patients taking cholesterol-lowering medication (statins) and 413 patients not using statins. Participants were randomly assigned to receive one of the following interventions: 400 mg per day of EPA plus DHA from fish oil, 2 grams of alpha-linolenic acid (ALA), a combination of these fatty acids, or a placebo.
Over the course of the study, major cardiovascular events occurred in approximately 13% of statin users and 15% of non-statin users. Among participants not taking statins, 18% of those receiving placebo experienced a major cardiovascular event, compared with 9% of those receiving fish oil. In contrast, among participants taking statin medication, no meaningful difference in cardiovascular event rates was observed between the placebo and omega-3 groups.
The authors concluded that statin treatment appeared to modify the effects of omega-3 fatty acids on the incidence of major cardiovascular events, suggesting an interaction between statin therapy and omega-3 supplementation.
It is also notable that, when event rates are examined across groups, the overall percentage of participants experiencing major cardiovascular events was lower in the fish-oil groups than in the statin-treated groups. This numerical observation, while not the primary focus of the authors’ conclusions, challenges common assumptions about the relative roles of drug-based and nutrient-based interventions in cardiovascular risk and highlights the importance of examining absolute outcomes rather than narrative framing alone.
